<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02749864</url>
  </required_header>
  <id_info>
    <org_study_id>JCG-PREVHEP-2015-01</org_study_id>
    <nct_id>NCT02749864</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP)</brief_title>
  <acronym>PREVHEP</acronym>
  <official_title>Personalized Medicine in HCV Infection. A Prospective, Multicenter, Epidemiological Study to Evaluate the Prevalence of Hepatitis C Infection in Spain in 2015 (PREVHEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Marqués de Valdecilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Marqués de Valdecilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this investigation stresses that the current understanding of the
      prevalence of HCV infection in the general population and in different subgroups will serve
      to lay out medium- and long-term measures for action geared toward reducing the disease
      burden through preventive, research, screening and therapeutic measures.

      Aim: To determine the prevalence of seropositivity and chronic infection with the HCV and to
      analyze the associated factors. To analyze and infer different screening strategies for HCV
      infection based on the at-risk groups/cohorts of elevated prevalence detected.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design of the study: Seroepidemiological and virological study of cross-sectional
      population-based.

      Patients and sampling: The study population has been distributed in groups according to age
      (20-34; 35-49; 50-79 years) and sex. The participants will be selected through a random,
      representative sample using our two-stage conglomerate sampling with stratification of the
      First-Stage Units. These FSUs are made up by the Basic Health Areas (Health Centers). The
      Second-Stage Units are made up by the individuals. The stratification criteria used in the
      first stage will be the socioeconomic status-rural/urban environment. The selection of sample
      elements will be carried out through simple random sampling from the healthcare card database
      pertaining to the selected Health Centers. A sequence of random, computer-generated numbers
      will be obtained.

      Sample size: In order to achieve an accuracy of 0.4% in the estimate of a percentage through
      a two-tailed 95% confidence interval, assuming the prevalences indicated by age strata in the
      general Spanish population (0.4%, 1.3% and 3.2% respectively), a total of 16,285 subjects
      distributed as follows: 1,303 aged 20-34 yr; 4397 aged 35-49 yr and 10,585 aged 50-79 yr.

      Considering that the subjects will be contacted by phone to invite them to participate in the
      study, and estimating a participation rate of 15%, should randomize 41.520 subjects.

      Recruitment method for randomized patients. Selected subjects will be called by phone by
      trained personnel. The subject will be invited to report for an interview in order to carry
      out a socio-healthcare questionnaire, a physical examination, and an analytical test. In the
      event the patient refuses to participate, permission shall be requested to collect minimum
      anonymous data for the subsequent study of possible screening biases. Patients meeting
      inclusion criteria and provide written informed consent to be included in the study.

      Variables in the study: socio-healthcare questionnaire includes variables such as age, sex,
      socioeconomic status, risk factors, health habits, etc. Analytical variables (blood count,
      biochemistry, serologies for HBV, HCV and HIV, etc.) are collected. A Fibroscan is also
      performed.

      Full duration: 18 months (Recruitment: 12 months, data generation and data analysis: 6
      months).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Anti-HCV</measure>
    <time_frame>1 day</time_frame>
    <description>Anti-HCV seroprevalence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCV RNA viral load</measure>
    <time_frame>1 day</time_frame>
    <description>Chronic HCV infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum HBsAg</measure>
    <time_frame>1 day</time_frame>
    <description>HBV portador status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum anti-HIV 1 and 2</measure>
    <time_frame>1 day</time_frame>
    <description>HIV serologic status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Birth date</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnaire about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sex</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnaire about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nationality</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnaire about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residence time in Spain</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnaire about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Educational level</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnaire about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity and professional qualifications</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnaire about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lifestyle habit/risk factor score</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnaire about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nosocomial risk score</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnaire about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History of previous check of HCV/HBV exposure</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnaire about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual behaviour</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnarie about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sexual partners</measure>
    <time_frame>1 day</time_frame>
    <description>Questionnaire about socio-economic and Health variables</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg)</measure>
    <time_frame>1 day</time_frame>
    <description>Weight (Anthropometric variables)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height (cm)</measure>
    <time_frame>1 day</time_frame>
    <description>Height (Anthropometric variables)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>1 day</time_frame>
    <description>Body Mass Index (Anthropometric variables)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal perimeter (cm)</measure>
    <time_frame>1 day</time_frame>
    <description>Abdominal perimeter (Anthropometric variables)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist perimeter (cm)</measure>
    <time_frame>1 day</time_frame>
    <description>Waist perimeter (Anthropometric variables)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure (mmHg)</measure>
    <time_frame>1 day</time_frame>
    <description>Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT</measure>
    <time_frame>1 day</time_frame>
    <description>Liver function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST</measure>
    <time_frame>1 day</time_frame>
    <description>Liver function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphatase (AP)</measure>
    <time_frame>1 day</time_frame>
    <description>Liver function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GGT (Gammaglutamyl transferase)</measure>
    <time_frame>1 day</time_frame>
    <description>Liver function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilirubin</measure>
    <time_frame>1 day</time_frame>
    <description>Liver function tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Albumin</measure>
    <time_frame>1 day</time_frame>
    <description>Biochemistry parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>1 day</time_frame>
    <description>Biochemistry parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>1 day</time_frame>
    <description>Biochemistry parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>1 day</time_frame>
    <description>Biochemistry parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>1 day</time_frame>
    <description>Biochemistry parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell count (WBC or leukocyte count)</measure>
    <time_frame>1 day</time_frame>
    <description>CBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>1 day</time_frame>
    <description>CBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelets</measure>
    <time_frame>1 day</time_frame>
    <description>CBC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>1 day</time_frame>
    <description>International Normalized Ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kPa in Fibroscan</measure>
    <time_frame>1 day</time_frame>
    <description>Liver stiffness</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">16000</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>A: Age 20-34 yr</arm_group_label>
    <description>No intervention Cohort of subjects aged 20-34 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Age 35-49 yr</arm_group_label>
    <description>No intervention Cohort of subjects aged 35-49 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Age 50-79 yr</arm_group_label>
    <description>No intervention Cohort of subjects aged 50-79 years old.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples of whole blood, plasma and serum will be collected to analyse different markers
      related to the virus and the medical status of the patients.

      DNA samples will be transferred to the Biobank Valdecilla (Node DNA and fluids) according to
      Spanish law. Law 14/2007 of 3 July, on biomedical research and the Biobank law:

      Royal Decree 1716/2011, establishing the basic requirements for authorization and operation
      of biobanks are established for biomedical research and treatment of biological samples of
      human origin
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        General population aged 20-79 years who agree to participate when contacted by phone call
        after a two-stage conglomerate sampling with stratification of the First-Stage Units.

        The study will be carried out in three Autonomous Communities (regions) in Spain.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 20 and 79 who have health card in each of the autonomous communities
             studied.

          -  They agree to participate, understand and give informed consent.

        Exclusion Criteria:

          -  Do not meet the criteria above.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Crespo García, MDPhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Gastroenterology and Hepatology at Hospital Universitario Marqués de Valdecilla. Professor at the Universidad de Cantabria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose L Calleja, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Gastroenterology and Hepatology at Hospital Universitario Puerta de Hierro-Majadahonda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel A Serra, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gastroenterology and Hepatology Department at Hospital Clínico U. de Valencia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Crespo García, MDPhD</last_name>
    <phone>34 942 202544</phone>
    <email>javiercrespo1991@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Cuadrado Lavín, MDPhD</last_name>
    <phone>34 942 202544</phone>
    <email>acuadrado@humv.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Crespo, MDPhD</last_name>
      <phone>34 942 20 25 44</phone>
      <email>javiercrespo1991@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Antonio Cuadrado, MDPhD</last_name>
      <phone>34 942 20 25 44</phone>
      <email>acuadrado@humv.es</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel A Serra, MDPhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro-Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José L Calleja, MDPhD</last_name>
      <email>joseluis.calleja@uam.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bruguera M, Forns X. [Hepatitis C in Spain]. Med Clin (Barc). 2006 Jun 17;127(3):113-7. Review. Spanish.</citation>
    <PMID>16828003</PMID>
  </reference>
  <reference>
    <citation>Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, Luma HN, Charlton M. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014 Apr;60(4):691-8. doi: 10.1016/j.jhep.2013.11.014. Epub 2013 Nov 27.</citation>
    <PMID>24291324</PMID>
  </reference>
  <reference>
    <citation>McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, Capretta JC, O'Grady MJ, Weinstein MC. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012 May;55(5):1344-55. doi: 10.1002/hep.25510. Epub 2012 Mar 18.</citation>
    <PMID>22135116</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2016</study_first_submitted>
  <study_first_submitted_qc>April 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2016</study_first_posted>
  <last_update_submitted>April 26, 2016</last_update_submitted>
  <last_update_submitted_qc>April 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis</keyword>
  <keyword>Prevalence</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>Infectious diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

